Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer

PURPOSE: Phosphatidylinositol 3-kinase (PI3K) inhibitors are being developed for the treatment of estrogen receptor α (ER)-positive breast cancer in combination with anti-estrogens. Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER+ breast cancer will provide r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Yang, Wei, Hosford, Sarah R., Dillon, Lloye M., Shee, Kevin, Liu, Stephanie C., Bean, Jennifer R., Salphati, Laurent, Pang, Jodie, Zhang, Xiaolin, Nannini, Michelle A., Demidenko, Eugene, Bates, Darcy, Lewis, Lionel D., Marotti, Jonathan D., Eastman, Alan R., Miller, Todd W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854767/
https://ncbi.nlm.nih.gov/pubmed/26733612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2276
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge